Eszopiclone Crystalline Form Stabilization via Chiral Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of zopiclone, particularly the racemic form, exhibit severe side effects and reduced efficacy due to its crystalline form instability, whereas a stable crystalline form of the S-isomer, eszopiclone, is needed for improved therapeutic effects and reduced toxicity.
Innovation Solution
A crystalline form of eszopiclone is developed using a process involving the reaction of racemic zopiclone with D-malic acid in a mixture of methanol and acetone, followed by solvent crystallization with ethyl acetate, characterized by specific X-ray diffraction, differential scanning calorimetry, and infrared absorption spectra, which stabilizes the compound and enhances its therapeutic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If racemic zopiclone is used for treatment, then sleep disorder can be treated, but severe side effects occur including bitter taste, dry mouth, drowsiness, and neuromotor function injury
Solution Approach 1:
The racemic zopiclone mixture is segmented into its enantiomeric components, isolating the active S-isomer (eszopiclone) from the R-isomer. This segmentation allows the therapeutic benefits of the S-isomer to be realized while eliminating the harmful effects associated with the R-isomer, thereby resolving the contradiction between therapeutic efficacy and side effects.
Solution Approach 2:
The harmful R-isomer is extracted and removed from the racemic mixture through chiral resolution processes. By taking out the inactive or harmful enantiomer, the patent achieves a purified S-isomer product that maintains therapeutic effectiveness while significantly reducing adverse reactions such as bitter taste, dry mouth, and neuromotor dysfunction.
2Reliability
If racemic zopiclone is used, then sleep disorder treatment is available, but toxicity is high compared to S-isomer
Solution Approach 1:
The racemic mixture is segmented into enantiomers, allowing isolation of the less toxic S-isomer. This segmentation demonstrates that the toxicity reduction is achieved by separating the harmful R-isomer component while retaining the therapeutic S-isomer, thus resolving the contradiction between availability and toxicity.
Solution Approach 2:
The toxic R-isomer is extracted and removed from the racemic preparation through chiral resolution methods. By taking out the harmful enantiomer, the patent achieves a purified S-isomer product that maintains therapeutic availability while significantly reducing acute toxicity and chronic adverse effects.
3Stability of the object's composition
If different crystalline forms of S-zopiclone are used, then physical properties vary, but no definite crystalline form has been reported leading to manufacturing inconsistencies
Solution Approach 1:
The patent applies parameter changes in the crystallization process, including controlled temperature gradients, solvent selection (ethyl acetate), and pH adjustment, to obtain a definite and stable crystalline form of S-zopiclone. These parameter optimizations ensure consistent crystal structure and physical properties, resolving the contradiction between compositional stability and manufacturing precision.
Solution Approach 2:
The patent utilizes controlled phase transitions during crystallization to achieve a stable crystalline form. By carefully controlling the solvent evaporation and cooling processes, the patent ensures reproducible crystal formation with consistent physical properties, thereby resolving the manufacturing inconsistency issue associated with polymorphic variations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline form of eszopiclone provides improved therapeutic efficacy for sleep disorders and anti-anxiety without affecting motor coordination, with enhanced stability and bioavailability, and is suitable for various pharmaceutical preparations.
Implementation Method 1
a method for preparing the crystalline form of S-zopiclone is provided, which comprises the following steps: (a). Dissolving S-zopiclone in ethyl acetate at a temperature ranging from 60° C. to a reflux temperature
Implementation Method 2
which is identified with a powder X-ray diffraction spectrum, a differential scanning calorimetry (DSC) and an infrared absorption spectrum (IR) clearly illustrated in the drawings, respectively
Implementation Method 3
A peak of DSC thermogram is at about 207.7° C.
Data Source
AI summary
The present invention discloses a crystalline form of S-zopiclone (Formula I) having a powder X-Ray diffraction spectrum excited by Cu-Ka radiation with characteristic peaks expressed in terms of 2θ at about 11.08°, about 12.38°, about 15.86°, about 17.88°, about 19. 98° and about 20.58°; a DSC thermogram with a peak at about 207.7° C. and an infrared absorption spectrum (IR) with characteristic peaks at about 3078 cm−1, about 2942˜2838 cm−1, about 2790 cm−1, about 1716 cm−1, about 1463 cm−1, about 1372 cm−1 and about 757 cm−1. The present invention also discloses a method for preparing the crystalline form of eszopiclone, its pharmaceutical composition and its use in preparing a medicament for treating sleep disorders.